Table 5 Group II (n = 51): Sensitivity, specificity and accuracy for urinary URO17® and urine cytology
From: The role of URO17® in diagnosis and follow up of bladder cancer patients
Cystoscopy | Sensitivity | Specificity | PPV | NPV | Accuracy | ||||
|---|---|---|---|---|---|---|---|---|---|
Free of malignancy (n = 44) | Recurrence of malignancy (n = 7) | ||||||||
No. | % | No. | % | ||||||
Urinary URO17® | |||||||||
Negative | 21 | 47.7 | 1 | 14.3 | 85.71 | 47.73 | 20.69 | 95.45 | 52.94 |
Positive for malignancy | 23 | 52.3 | 6 | 85.7 | |||||
χ2 (FEP) | 2.753 (0.124) | ||||||||
Urine cytology | |||||||||
Inflammatory | 41 | 93.2 | 5 | 71.4 | 28.57 | 93.57 | 40.0 | 89.13 | 84.31 |
Positive for malignancy | 3 | 6.8 | 2 | 28.6 | |||||
χ2 (FEP) | 3.232 (0.133) | ||||||||